新聞中心
新聞新發(fā)展新型冠狀病毒2019-nCoV核酸檢測(cè)試劑盒(熒光RT-RAA法)完成三家臨床評(píng)估
中國(guó)疾病預(yù)防中心病毒病預(yù)防控制所 和 江蘇奇天基因生物科技有限公司 聯(lián)合研制的新型冠狀病毒( 2019-nCoV )核酸等溫?cái)U(kuò)增快速檢測(cè)試劑盒分別在浙江大學(xué)醫(yī)學(xué)院附屬第一醫(yī)院( 92 例臨床標(biāo)本),浙江省疾病預(yù)防控制中心( 104 例臨床標(biāo)本)和江蘇省疾病預(yù)防控制中心( 100 例標(biāo)本)完成了臨床評(píng)估。標(biāo)本在提取核酸后,使用本試劑盒檢測(cè)新型冠狀病毒核酸 8-15 分鐘 出檢測(cè)結(jié)果 。經(jīng)分別與藥監(jiān)局批準(zhǔn)的商業(yè)化定量 PCR 試劑盒平行比較,試劑盒的陽(yáng)性符合率 100% ,陰性符合率 100% , 總符合率 100% ,具有等效性。該試劑盒被上述評(píng)價(jià)單位推薦用于臨床 2019-nCoV 的定性檢測(cè),鑒別 2019-nCoV 疑似感染的病人。該試劑盒適宜于在地市級(jí)實(shí)驗(yàn)室使用。目前該試劑盒正在申報(bào)藥監(jiān)局批準(zhǔn)文號(hào)。
疾控中心病毒病預(yù)防控制所研發(fā)團(tuán)隊(duì)于2020年4月,在《 Clinical Microbiology and Infection 》 上 發(fā)表了相關(guān)文章: 標(biāo)題為:《 A multiple center clinical evaluation of an ultra-fast single-tube assay for SARS-CoV-2 RNA 》。摘要內(nèi)容如下:
Abstract
Objectives: To evaluate the performance of an ultra-fast single-tube nucleic acid isothermal amplification detection assay for SARS-CoV-2 RNA using clinical samples from 44 multiple centers.
Methods: A reverse transcription recombinase-aided amplification (RT-RAA) assay for SARS-CoV-2 was conducted within 15minutesat39? with portable instruments after addition of extracted RNA. The clinical performance of RT-RAA assay was evaluated using 947 clinical samples from five institutions in four regions of China, and the approved commercial real-time fluorescent RT-PCR (qRT-PCR) kits were used for parallel detection. The sensitivity and specificity of RT-RAA were compared and analyzed.
Results: The RT-RAA test results of 926 samples were consistent with those of qRT-PCR (330 were positive, 596 were negative) and 21 were inconsistent. The sensitivity and specificity of RT-RAA was 97.63% [330/338, 95% confidence interval (CI): 95.21 to 98.90] and 97.87% (596/609, 95% CI: 96.28 to 98.81), respectively. The positive predictive value (PPV) and negative predictive value (NPV) were 96.21% (330/343, 95% CI: 93.45 to 97.88), and 98.68% (596/604, 95% CI: 97.30 to 99.38), respectively. The total coincidence rate was 97.78% (926/947, 95% CI: 96.80 to 98.70) and the Kappa was 0.952 (P <0.05).
Conclusion: With comparable sensitivity and specificity to the commercial qRT-PCR kits, RT-RAA assay for SARS-CoV-2 exhibited distinctive advantages of simplicity and rapidity in terms of operation and turn-around time.
公眾號(hào)二維碼
客服微信號(hào)
服務(wù)熱線:
0510-85385531電話:
18921157475地址:
無錫市新吳區(qū)菱湖大道97號(hào)興業(yè)樓B棟4-5F我的網(wǎng)站 版權(quán)所有:江蘇奇天基因生物科技有限公司 蘇ICP備14035831號(hào)-1 COPYRIGHT@2012-2023 qt-bio.com All Rights Reserved.